IOVS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

(Investigative Ophthalmology and Visual Science. 2007;48:1181-1190.)
© 2007 by The Association for Research in Vision and Ophthalmology, Inc.
doi:10.1167/iovs.05-1213
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (6)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bakalash, S.
Right arrow Articles by Schwartz, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bakalash, S.
Right arrow Articles by Schwartz, M.

Chondroitin Sulfate-Derived Disaccharide Protects Retinal Cells from Elevated Intraocular Pressure in Aged and Immunocompromised Rats

Sharon Bakalash,1,2 Asya Rolls,1,2 Ofer Lider,3,4 and Michal Schwartz1

1From the Departments of Neurobiology and 3Immunology, The Weizmann Institute of Science, Rehovot, Israel.

PURPOSE. A disaccharide (DS) derived from the naturally occurring compound chondroitin sulfate proteoglycan (CSPG) was recently shown to have neuroprotective activity. The authors examined the ability of this compound (CSPG-DS) to protect retinal ganglion cells (RGCs) from death caused by elevated intraocular pressure (IOP).

METHODS. With the use of chronic and acute models of elevated IOP, the authors examined the effects of CSPG-DS on RGC survival in adult (~2 months old), aged (10–12 months old), and immunocompromised Lewis rats. Systemic, topical, and oral routes of administration were examined.

RESULTS. CSPG-DS protected RGCs from IOP-induced death. Treatment was effective in all three examined rat populations (normal adult, aged, and immunocompromised rats) and with all routes of administration, possibly in part through its control of microglial activity.

CONCLUSIONS. Results point to the therapeutic potential of CSPG-DS for glaucoma, particularly in elderly populations for whom disease prevalence is high.




This article has been cited by other articles:


Home page
 J. Leukoc. Biol.Home page
S. Ebert, T. Schoeberl, Y. Walczak, K. Stoecker, T. Stempfl, C. Moehle, B. H. F. Weber, and T. Langmann
Chondroitin sulfate disaccharide stimulates microglia to adopt a novel regulatory phenotype
J. Leukoc. Biol., September 1, 2008; 84(3): 736 - 740.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by the Association for Research in Vision and Ophthalmology